Aurora Innovation, Inc. — Form 8-K Summary
Business Context and Reporting Period
Aurora Innovation, Inc. filed a Form 8-K reporting actions taken by its Compensation Committee on August 14, 2023. The report was signed on August 18, 2023. The filing concerns a new Change in Control and Severance Policy for designated employees, including named executive officers.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes
- The Compensation Committee approved a standardized three-year Change in Control and Severance Policy, which automatically renews for additional one-year terms unless the Company elects not to renew.
- The policy applies to eligible employees designated by the Committee and includes the Company’s named executive officers.
Severance and Change in Control Provisions
- Following a change in control: If an eligible employee experiences an involuntary termination within the change in control period, defined as the period beginning on the change in control date and ending 12 months afterward, and satisfies the release requirement, the employee may receive 100% of annual base salary, 100% of the target bonus for the termination year prorated for full months employed, COBRA medical premium payments or reimbursement for up to 12 months, and accelerated vesting of 100% of outstanding unvested time-based equity awards.
- Outside a change in control period: If an eligible employee is terminated other than for cause, death, or disability, and satisfies the release requirement, the employee may receive six months of base-salary severance and COBRA medical premium payments or reimbursement for up to six months.
- Change-in-control benefits require an involuntary termination, which includes termination without cause or resignation for good reason, as defined in the policy.
- Eligible employees must execute an irrevocable separation agreement and release of claims within 60 days following termination.
Risks, Contingencies, and Unusual Items
The policy creates potential future cash, medical-benefit, and equity-compensation obligations upon qualifying terminations. The filing does not quantify the potential aggregate cost or identify the employees designated as participants beyond stating that named executive officers will be included. Benefits are contingent on the applicable termination circumstances and execution of the required release.
Investor Verification Items
- Review Exhibit 10.1 for the complete definitions of “cause,” “good reason,” “change in control,” and other eligibility conditions.
- Verify the employees designated as eligible participants and the applicable base salaries, target bonuses, and equity awards.
- Assess the potential dilution and expense implications of accelerated vesting.
- Confirm the policy’s renewal and non-renewal provisions and any subsequent amendments or replacement arrangements.